4 Healthcare Stock Stories For Tuesday Investment Wellness

Biogen IDEC (NASDAQ: BIIB): Current price $201.70

The United States Court of Appeals for the Federal Circuit in Washington has ruled against an appeal made by Biogen and Roche’s Genetech in a patent infringement case against GlaxoSmithKline (NYSE: GSK). The court decided that a United States judge was correct with his interpretation of a Biogen patent that covers the cancer drug Arzerra. Based on the judge’s definition, Glaxo did not infringe the patent.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BIIB

Eli Lilly and Company (NYSE:LLY): Current price $57.18

On Tuesday the firm reported positive top-line results of two additional Phase III AWARD  trials for dulaglutide, which is an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. Primary efficacy endpoints of non-inferiority to insulin glargine, as measured by the reduction of hemoglobin A1c (HbA1c) levels at the 1.5 mg dose, were attained in two evaluations (AWARD-2 and AWARD-4). Having met the primary endpoints, superiority for HbA1c lowering was studied.  The dulaglutide 1.5 mg dose showed statistically superior reduction in HbA1c from baseline, compared to insulin glargine at 52 weeks in patients suffering from type 2 diabetes on metformin and glimeperide (AWARD-2).

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LLY

Northwest Biotherapeutics (NASDAQ:NWBO): Current price $4.10

The biotechnology company announced Tuesday that its Phase III clinical trial for Glioblastoma multiforme brain cancer has been adopted as a national priority trial in the United Kingdom, under the adoption program overseen by the National Institute for Health Research, which forms part of the National Health System.  This adoption of the firm’s Phase III trial constitutes a significant validation, and also carries with it resources and operational support for the trial sites.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

NWBO

Gentium (NASDAQ:GENT): Current price $7.89

The firm announced that it has asked for a re-examination of the negative opinion adopted by theEuropean Medicines Agency’s Committee for Medicinal Products for Human Use on March 22, concerning the Marketing Authorization submitted for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children who are undergoing hematopoietic stem cell transplantation therapy. In accordance with European regulations, Gentium has 60 days to submit grounds for appeal and the CHMP has further 60 days to consider a revision of the initial opinion.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GENT

Don’t Miss: Are Johnson & Johnson’s Recall Nightmares Over?

More from The Cheat Sheet